ANY QUESTIONS?BMJ 1995; 310 doi: https://doi.org/10.1136/bmj.310.6987.1118 (Published 29 April 1995) Cite this as: BMJ 1995;310:1118
- T W Meade
What is the rationale of using a combination of aspirin and warfarin in thromboembolic conditions?
The haemostatic system contributes platelet aggregates and fibrin deposits to occlusive thombi. On the arterial side trials have shown that antiplatelet drugs (principally aspirin) or anticoagulants (heparin or warfarin, or both) on their own result in worthwhile reductions in the recurrence of major cardiovascular episodes. The value of thrombolytic agents in the early stages of myocardial infarction is also well established. An obvious question is whether modifying platelet behaviour and fibrin deposition simultaneously may be more effective than either approach on its own.
Until fairly recently, combined regimens have generally been avoided because of their expected …